- Home
- SUNC vs ELVN Comparison
SUNC vs ELVN Comparison
Compare SUNC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUNC | ELVN |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.2B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUNC | ELVN |
|---|---|---|
| Price | $75.79 | $44.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $61.00 | $43.40 |
| AVG Volume (30 Days) | 370.4K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 2.89 | N/A |
| Revenue | ★ $25,201,000,000.00 | N/A |
| Revenue This Year | $65.29 | N/A |
| Revenue Next Year | $0.84 | N/A |
| P/E Ratio | $26.74 | ★ N/A |
| Revenue Growth | ★ 11.05 | N/A |
| 52 Week Low | $47.00 | $14.79 |
| 52 Week High | $83.50 | $62.32 |
Technical Indicators
Market Signals| Indicator | SUNC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 19.15 |
| Support Level | $74.68 | $38.58 |
| Resistance Level | $78.21 | $48.53 |
| Average True Range (ATR) | 2.10 | 2.20 |
| MACD | -0.74 | -1.17 |
| Stochastic Oscillator | 4.04 | 0.00 |
Price Performance
Historical ComparisonAbout SUNC SunocoCorp LLC
SunocoCorp LLC is a publicly traded limited liability company that owns a direct limited partner interest in Sunoco LP. It engages in the management and distribution of fuel products. It operates through the following segments: Fuel Distribution, Pipeline Systems, and Terminals and Refinery.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.